{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033729","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.305313+00:00","generated_at":"2026-05-30T03:39:32.241464+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eton Pharma awarded second patent for ET-400; PDUFA target Feb 28, 2025","bullets":["USPTO granted U.S. Patent No. 12,133,914 for ET-400 (liquid hydrocortisone), expiring 2043.","Second patent for ET-400; first patent (US 11,904,046) obtained in February 2024.","Additional U.S. patent application for ET-400 remains under review.","FDA NDA accepted with PDUFA target action date of February 28, 2025.","If approved, ET-400 would be the only FDA-approved liquid hydrocortisone formulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033729","json":"https://secwatch.observer/filing/0001437749-24-033729.json","markdown":"https://secwatch.observer/filing/0001437749-24-033729.md","text":"https://secwatch.observer/filing/0001437749-24-033729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924033729/0001437749-24-033729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924033729/eton20241105_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:39:32.241464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}